Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
AbbVie
Hunan Province Tumor Hospital
Boehringer Ingelheim
Shanghai JMT-Bio Inc.
BioNTech SE
Hoffmann-La Roche
University of Chicago
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Amgen
Debiopharm International SA
Amgen
Merck Sharp & Dohme LLC
University of Maryland, Baltimore
Hoffmann-La Roche
BioNTech SE
Hoffmann-La Roche
AstraZeneca
SWOG Cancer Research Network
The Second Affiliated Hospital of Dalian Medical University
NRG Oncology
Boehringer Ingelheim
Big Ten Cancer Research Consortium
Tang-Du Hospital
Shanghai Henlius Biotech
Shanghai Junshi Bioscience Co., Ltd.
Sichuan University
Mayo Clinic
Akeso
AstraZeneca
Bristol-Myers Squibb
Swiss Cancer Institute
G1 Therapeutics, Inc.
Anhui Provincial Cancer Hospital
Trans Tasman Radiation Oncology Group
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Cancer Institute (NCI)
RayzeBio, Inc.
Merck Sharp & Dohme LLC
Shanghai Pulmonary Hospital, Shanghai, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Merck Sharp & Dohme LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center